{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-006200","form_type":"8-K","ticker":"HRMY","cik":"0001802665","company_name":"Harmony Biosciences Holdings, Inc.","filed_at":"2024-04-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.193554+00:00","generated_at":"2026-06-03T04:38:01.316668+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Harmony Biosciences Q1 revenue $154.6M (+30% YoY); reaffirms FY2024 guidance $700-720M","bullets":["Q1 net revenue $154.6M (+30% YoY); GAAP EPS $0.67, adjusted EPS $0.88.","Reaffirmed FY 2024 net revenue guidance of $700-720M.","Pipeline: sNDA for pitolisant in IH planned H2 2024; pediatric narcolepsy PDUFA June 21, 2024.","Licensed TPM-1116 (orexin-2 agonist) for narcolepsy; IND expected mid-2025.","Acquired Epygenix for rare epilepsy; clemizole Dravet/LGS pivotal trial topline 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-006200","json":"https://secwatch.observer/filing/0001558370-24-006200.json","markdown":"https://secwatch.observer/filing/0001558370-24-006200.md","text":"https://secwatch.observer/filing/0001558370-24-006200.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1802665/000155837024006200/0001558370-24-006200-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1802665/000155837024006200/hrmy-20240430x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T04:38:01.316668+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0fb7041885e57a77539709d360210bb268b9ad5b","claim":"Harmony Biosciences Holdings, Inc. reported Q1 2024 results: revenue WAKIX Net Revenue of $154.6 Million, net income GAAP net income for the quarter ended March 31, 2024, was $38.3 million, EPS $0.67 per diluted share. Guidance reaffirmed.","evidence_excerpt":"ADVANCES PITOLISANT FRANCHISE TO EXTEND REVENUE POTENTIAL BEYOND 2040; STRENGHTENS SLEEP/WAKE LEADERSHIP AND DIVERSIFIES INTO RARE EPILEPSY ​ WAKIX® (pitolisant) Net Revenue of $154.6 Million for First Quarter 2024; ~30% Growth Year-over-Year ​ Supplemental New Drug Application for Pitolisant in Idiopathic Hypersomnia Planned for Second Half 2024 ​ On Track Toward","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1802665/000155837024006200/0001558370-24-006200-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Q1 2024"},{"label":"Revenue","value":"WAKIX Net Revenue of $154.6 Million"},{"label":"Net income","value":"GAAP net income for the quarter ended March 31, 2024, was $38.3 million"},{"label":"EPS","value":"$0.67 per diluted share"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}